NCT06406231 Magnetic Field Therapy Versus Transcutaneous Electrical Nerve-stimulation in Knee Osteoarthritis
| NCT ID | NCT06406231 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Tunis El Manar |
| Condition | Knee Osteoarthritis |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2023-09-15 |
| Primary Completion | 2024-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2023-09-15 with a primary completion date of 2024-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The effectiveness of PEMF in improving physical function among Osteoarthritic (OA) patients remains a topic of debate, leading to the American College of Rheumatology not yet endorsing its use in OA treatment. Therefore, it's essential to investigate PEMF therapy's efficacy in alleviating joint pain, stiffness, and enhancing physical function in knee OA patients Our study objectives were to evaluate the effectiveness and safety of PEMF therapy and to compare its efficacy with TENS in knee OA management.
Eligibility Criteria
Inclusion Criteria: * We included patients who had knee pain due to knee OA diagnosed according to the American College of Rheumatology including: * Knee pain AND presence of at least three of the following 6 criteria: * Age \> 50 years * Morning stiffness \< 30 minutes * Crepitus during movement * Periarticular bone pain * Periarticular bone hypertrophy * Absence of increased local warmth. Exclusion Criteria: * For both groups, we did not include: * Patients with a pacemaker, implantable defibrillator, cochlear implant, or any metal implant contraindicating MRI (knee prosthesis, hip prosthesis, etc.). * Pregnant women * Patients with an active infection * Profound hypoesthesia or thermoalgic sensitivity disorder * Poorly vascularized areas: arteritis, phlebitis, ischemia * Patients on anti-vitamin K treatment or with a coagulation disorder. Patients with long-term corticosteroid therapy or having a total knee replacement, those who have received therapies for knee osteoarthritis including intra-articular corticosteroid injection or viscosupplementation in the last 4 months, and Patients with knee pain of non-osteoarthritic origin were also not included in the study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06406231 clinical trial?
This trial is open to participants of all sexes, studying Knee Osteoarthritis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06406231 currently recruiting?
Yes, NCT06406231 is actively recruiting participants. Contact the research team at emna.razgallah123@gmail.com for enrollment information.
Where is the NCT06406231 trial being conducted?
This trial is being conducted at Tunis, Tunisia.
Who is sponsoring the NCT06406231 clinical trial?
NCT06406231 is sponsored by University Tunis El Manar. The trial plans to enroll 60 participants.